Tongee Medical Technology

What Tongee Medical Technology does

Tongee Medical Technology (Hangzhou Tongee Medical Technology Co., Ltd. / 杭州糖吉医疗科技有限公司) is a privately held Chinese medical device company founded in 2016 and headquartered in Hangzhou. It develops interventional gastrointestinal devices and digital health platforms for metabolic diseases, with a flagship product line centered on the Gastric Bypass Stent System (胃转流支架系统) — a 60cm duodenal stent placed endoscopically to create a "metabolic regulation channel" delivering combined physical and hormonal weight control for patients with obesity, Type 2 diabetes, and metabolic dysfunction-associated fatty liver disease (MASH/NASH). The system is the world's first Class III innovative medical device approved by China's NMPA for endoscopic obesity treatment (January 2024) and holds US FDA Breakthrough Device Designation (October 2024). The technology stack is anchored by three layers: the stent system as the core intervention, a metabolism-specific Electronic Upper Gastrointestinal Endoscope System (NMPA-approved December 2025) as the dedicated delivery and diagnostic platform, and the DTx Digital Metabolic Health Management Platform (China's first medical device-registered weight-loss software) as the AI-supported chronic care layer. Pipeline products include a degradable intragastric balloon (first pivotal trial implantation completed in 2025) and a superabsorbent hydrogel.

The company generates revenue primarily through hardware sales of Class III medical devices to hospitals on a per-procedure/per-device basis, with no public pricing disclosed. Its go-to-market combines direct engagement with Grade-3A hospitals and a national distributor network of approximately 100 partners supporting regional coverage in China. Internationally, the company follows a country-by-country regulatory registration model, with the Gastric Bypass Stent System now registered in 11 countries/regions (six in Southeast Asia, one in the Middle East, three in South America, plus Hong Kong) and international KOLs (Dr. Handy Wing in Indonesia, Prof. Yelong Yeh Lee in Malaysia) anchoring adoption. As of May 2026, the device has been implanted in over 3,000 cases across more than 350 hospitals in 29 Chinese provinces, supported by clinical evidence showing approximately 10% body weight reduction at three months, and >60% MASH resolution and >50% liver fibrosis improvement at six months. Strategic distribution partnerships include collaborations with Youjia Biotech on siRNA metabolic disease research and with Shanghai International Medical Center on a Medical Weight Loss-Assisted Reproduction Alliance and training base.

Name

Tongee Medical Technology

Legal name

Hangzhou Tongee Medical Technology Co., Ltd.

Website

https://tangjimed.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

Tongee Medical Technology is a Hangzhou-based privately held medical device company that develops endoscopic gastrointestinal devices and digital health platforms to treat metabolic diseases, including obesity, Type 2 diabetes, and MASH/NASH, selling primarily to hospitals across China and 11 international markets.

Ownership category

akta.pro rank

Product category

Interventional Metabolic Disease Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

akta.pro secondary industries

Obesity Medicine & Weight Management (HLAKADAL), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Endoscopic bariatric devices
• Metabolic disease treatment
• Interventional medical devices
• Digestive endoscopy equipment
• Digital therapy platforms

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales: Sale of proprietary medical devices (gastric bypass stent system, electronic endoscopes, intragastric balloons) to hospitals and medical institutions. Revenue is generated on a per-procedure/per-device basis. The company maintains a domestic hospital network of 350+ institutions and an international network across 11 countries and regions.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Tongee Medical Technology develops, manufactures, and commercializes endoscopic interventional medical devices for treating metabolic diseases, with its flagship being the Gastric Bypass Stent System — the world's first NMPA-approved Class III innovative device for endoscopic obesity treatment. The product portfolio includes a metabolism-specific Electronic Upper Gastrointestinal Endoscope System that delivers and diagnoses, plus an AI-powered DTx digital metabolic health management platform. Devices are sold to hospitals and clinics for endoscopic implantation procedures on patients with obesity, Type 2 diabetes, and MASH/NASH.

Product overview

Tongee Medical Technology is a medical device company dedicated to building an innovative platform for interventional gastrointestinal therapies and related medical equipment, disease management and solutions. The company offers a comprehensive product ecosystem centered on the Gastric Bypass Stent System (world's first Class III innovative medical device for endoscopic obesity treatment), complemented by the Electronic Upper Gastrointestinal Endoscope System (powered diagnostic equipment serving as the stent delivery platform), and the DTx Digital Health Management Platform (AI-powered software providing full-cycle chronic disease management). The portfolio is further expanded through pipeline products including the Degradable Intragastric Balloon and Superabsorbent Hydrogel, along with nutritional accessory products like the Nutritional Meal Replacement Shake. Together, these products and platforms cover the full metabolic disease intervention lifecycle from screening, treatment, rehabilitation, to long-term management.

Differentiator

Problem solved

Functional benefit

Products and services

• Gastric Bypass Stent System (胃转流支架系统) World's first Class III innovative medical device for endoscopic treatment of obesity. A 60cm stent placed in the duodenum creates a metabolic regulation channel achieving dual weight control through physical intervention and hormonal regulation. Super minimally invasive placement, reversible, repeatable, with no anatomical structure damage. Targets moderate-to-severe obesity, Type 2 diabetes, and MASH/NASH. Sold to hospitals for implantation procedures.
• Electronic Upper Gastrointestinal Endoscope System (糖吉电子上消化道内窥镜系统) China's first metabolism-specific electronic endoscope with ultra-long shaft optimized for patients with abdominal fat accumulation and deeper upper GI tract anatomy, covering the distal duodenum and proximal jejunum. Serves as the primary delivery and diagnostic platform for the Gastric Bypass Stent System. Sold to hospitals as standalone diagnostic and procedural equipment.
• DTx Digital Metabolic Health Management Platform (DTx数字健康管理平台) AI-powered digital therapy platform for chronic metabolic disease management integrating artificial intelligence algorithms for monitoring and treatment support. Forms a closed-loop with the Gastric Bypass Stent System by combining offline treatment with online management. Licensed/sold to hospitals and clinicians for managing implanted patients.
• Degradable Intragastric Balloon (可降解胃内球囊) Degradable intragastric balloon in development for endoscopic weight loss treatment. Targets the same patient population as the Gastric Bypass Stent System, providing a differentiated option within the interventional treatment range. Currently in clinical trial phase.
• Nutritional Meal Replacement Shake (营养简餐奶昔) Patent-protected calorie control water bead technology product for patient nutrition management. Provides meal replacement with delicate texture and lasting satiety, supporting patient nutrition management in metabolic disease treatment. Recommended as an accessory to support the broader metabolic disease treatment program.

Quantifiable outcome

• Average ~10% body weight reduction in 3 months (super-minimally invasive approach)
• +6 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Shanghai International Medical Center (SIMC)coreStrategic or Co-development Partner · 12 December 2025Co-founded the Medical Weight Loss-Assisted Reproduction Alliance and established the Tongee Gastric Bypass Stent SIMC Training Base. Joint platform for cross-disciplinary collaboration between endocrinology, reproductive medicine, and endoscopic weight loss. Aims to standardize and promote endoscopic weight loss in assisted reproduction, building the base into a specialized training and technology promotion hub.
• Youjia Biotech (佑嘉生物)coreStrategic or Co-development Partner · 3 December 2025Strategic partnership for small interfering RNA (siRNA) innovative drug R&D platform applied to metabolic disease treatment. Tongee contributes clinical resources and market understanding; Youjia contributes siRNA drug development expertise. Aims to explore metabolic regulation pathways at the gene level and advance from 'solving clinical pain points' to 'decoding scientific mechanisms.' Represents Tongee's first step into foundational metabolic disease research beyond device intervention.
• Dr. Handy Wing (Indonesia)coreStrategic or Co-development Partner · 4 September 2025First international expert to receive gastric bypass stent system training certificate. Performed Southeast Asia's first clinical implantation (Jakarta, Indonesia, September 2025). Key opinion leader driving adoption of the technology in Southeast Asia.
• Beijing Friendship Hospital Affiliated to Capital University of Medical SciencescoreStrategic or Co-development PartnerNational Clinical Research Center for Gastrointestinal Diseases. Collaborative hospital for clinical research and development of the gastric bypass stent system. ISO9001-certified biological sample bank and medical ethics platform.
• Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing UniversitycoreStrategic or Co-development PartnerRanked 37th in 2019 Fudan General Hospital Ranking. Collaborative hospital for gastric bypass stent clinical practice and research. Three-time winner of National Satisfactory Medical Institution title.
• Beijing Shijitan Hospital, Capital Medical UniversityminorStrategic or Co-development PartnerCollaborative hospital with key gastroenterology and gastrointestinal hepatobiliary surgery disciplines. Average annual research funding exceeding 10 million yuan. Multiple national and provincial scientific research awards.
• Tianjin Medical University General HospitalminorStrategic or Co-development PartnerOne of the five large central hospitals in 1946 China. National 'Double First-Class' university affiliated hospital. Leading provider of endoscopy and intervention training in northern China.
• Hospital of Air Force Medical UniversityminorStrategic or Co-development PartnerModern Grade-3A hospital with major research awards including National Science and Technology Progress Award (first prize) and National Technological Invention Award (second prize). Research funding exceeding 200 million yuan since the 13th Five-Year Plan.
• The First Hospital of China Medical UniversityminorStrategic or Co-development PartnerGrade-3A hospital ranked 15th nationally in Fudan 2021 hospital ranking; ranked first in Northeast China for 12 consecutive years. 4 national key disciplines and 1 national clinical medical research center.
• The Affiliated Hospital of Inner Mongolia Medical UniversityminorStrategic or Co-development PartnerGrade-3A hospital in Inner Mongolia with complete disciplines and multidisciplinary advantages. National Model Hospital and Top 100 Hospital recipient.
• Prof. Yelong Yeh Lee (Malaysia)minorStrategic or Co-development PartnerFormer President of Malaysian Society of Gastroenterology and Hepatology (MSGH). Expressed strong interest in visiting China for systematic training and conducting Malaysia's first gastric bypass stent implantation.
• Jiangsu Provincial People's Hospital (协办方)minorStrategic or Co-development PartnerCo-organizer of the 2026 'Star Cup' 2nd National Gastric Bypass Stent Case Competition (East China Division). Served as competition host venue with Prof. Liang Hui as competition chairman.

Scale indicators9 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• GI Dynamics: Developer of EndoBarrier, a duodenal-jejunal bypass liner for endoscopic treatment of Type 2 diabetes and obesity. The most direct competitor to Tongee's Gastric Bypass Stent System, using a similar duodenal intervention mechanism for metabolic disease.
• USGI Medical: Developer of incisionless endoscopic procedures (g-Cath EZ, g-Lix) for bariatric applications including endoscopic sleeve gastroplasty. Competitor offering endoscopic tools for primary obesity interventions in hospitals.
• Allurion Technologies: Developer of the Allurion Balloon, a swallowable, procedure-less gastric balloon for weight loss. Competitor in the endoscopic/minimally invasive obesity device space targeting similar patient populations seeking non-surgical intervention.

Emerging players

• Endogastric Solutions: Developer of EsophyX device for transoral fundoplication and adjacent endoscopic procedures. Emerging player in endoscopic therapeutic device space relevant to Tongee's expanding endoscope-based metabolic therapy portfolio.
• Fractyl Health: Developer of Revita DMR, an endoscopic duodenal mucosal resurfacing procedure for Type 2 diabetes and metabolic disease. Competitor in the endoscopic metabolic intervention space with a similar mechanism rationale (duodenal intervention for metabolic regulation).
• Spatz FGIA: Developer of Spatz3, an adjustable intragastric balloon. Smaller specialty player competing in the non-surgical endoscopic weight loss device category with Tongee's degradable balloon pipeline.

Broad incumbents

• Novo Nordisk: Maker of Wegovy (semaglutide) and Ozempic, GLP-1 receptor agonists that have redefined obesity treatment. Not a direct device competitor but a major alternative therapy reshaping patient and payer preferences for obesity treatment.
• Eli Lilly: Maker of Mounjaro/Zepbound (tirzepatide), a dual GIP/GLP-1 agonist delivering 20%+ weight loss. Represents the most aggressive pharmacotherapy threat to endoscopic obesity devices like Tongee's Gastric Bypass Stent.
• Medtronic: Global medical device incumbent offering a range of endoscopic instruments, bariatric surgical products, and metabolic disease devices. Competes with Tongee's electronic endoscope and represents a large strategic that could enter the endoscopic obesity device space.
• Boston Scientific (Apollo Endosurgery): Acquired Apollo Endosurgery (maker of Orbera intragastric balloon and OverStitch endoscopic suturing system). A broad incumbent offering endoscopic bariatric and metabolic therapy products competing in the minimally invasive obesity treatment market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/HangzhouTangji
• Facebookfacebook.com/100061747580101

Compliance17 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tongee Medical Technology